A Comprehensive Psychometric Validation of EQ Instruments for Early Childhood Health-Related Quality of Life and Caregiver Spillover
A Comprehensive Psychometric Validation of EQ Instruments for Early Childhood Health-Related Quality of Life and Caregiver Spillover, Including EQ-TIPS, EQ-5D-Y-5L, EQ-5D-5L With Sleep and Fatigue Bolt-ons, and the EQ-HWB-9
This study aims to address critical gaps in the measurement of health-related quality of life (HRQoL) in children under the age of five by conducting a comprehensive psychometric validation of the EQ-TIPS instrument, including both 3-level and 5-level versions. We will conduct a longitudinal study using both quantitative and qualitative methods to assess the feasibility, face validity, known-groups validity, test-retest reliability, and responsiveness of both EQ-TIPS-3L and EQ-TIPS-5L in children aged 0-48 months. For children aged 25-48 months, we will also examine the comparability and potential transition between EQ-TIPS-5L and the proxy version of EQ-5D-Y-5L. In addition, we aim to explore spillover effects on family carers by evaluating the psychometric performance, such as known-groups validity, test-retest reliability, and responsiveness of two newly developed EQ-5D-5L bolt-on items (sleep and fatigue) and the EQ-HWB-9. A total of 450 participants will be recruited from three tertiary hospitals in China across three health condition groups: acute illnesses (n=180), chronic conditions (n=180), and healthy controls (n=90), with an approximately balanced distribution across age groups and disease severity levels. The survey questionnaires will include two parts: 1) Child section: EQ-TIPS-3L, EQ-TIPS-5L, proxy EQ VAS, EQ-5D-Y-5L proxy version 1 (only for children aged 25-48 months), a 5-grade overall health assessment (OHA) proxy version, QQ-10 questionnaire, and children's demographic information; 2) Carer section: carers' EQ-5D-5L with sleep and fatigue bolt-ons, carers' EQ VAS, carers' EQ-HWB-9, and carers' demographic information. Each clinical condition is selected for its high prevalence and clinical relevance in early childhood, as well as its suitability for stratifying health status by severity. Additionally, to assess face validity, carers will complete the QQ-10 questionnaire after completing the EQ-TIPS questionnaire to provide structured feedback on the clarity, relevance, and acceptability of EQ-TIPS. Findings will contribute essential evidence to support the use of EQ-TIPS in early childhood HRQoL assessment and of the EQ-5D-5L bolt-ons and EQ-HWB-9 in evaluating caregiver spillover effects. The study data will be shared with the EuroQol Group to support future development and application of these instruments.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Wenjing Zhou, PhD
- Phone Number: 86-13817114768
- Email: zhoujing2188@163.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
The study population will consist of 450 children aged 0-48 months and their primary family carers recruited from three tertiary hospitals in China. Participants will be enrolled into three groups: acute illnesses (pneumonia and diarrhoea, n=180), chronic conditions (haematological malignancies and asthma, n=180), and healthy controls (n=90). Recruitment will aim for balanced representation across age groups (0-24 and 25-48 months) and disease severity levels. Children with illnesses will be recruited from outpatient clinics and inpatient departments, while healthy controls will be recruited during routine physical examinations. Primary family carers will serve as proxy respondents for child health assessments and complete questionnaires assessing their own health and well-being.
Description
Inclusion Criteria:
- -Children aged 0-48 months at enrolment.
- Children diagnosed with pneumonia, acute diarrhoea, haematological malignancies, or asthma; or healthy children without known medical conditions attending routine physical examinations.
- Availability of a primary family carer (parent, grandparent, or legal guardian) who has primarily cared for the child during the preceding month, including supervision of daily activities and health-related care.
- The primary family carer accompanies the child during the outpatient visit, inpatient admission, or routine physical examination.
- The primary family carer is able to understand the study information and provides written informed consent.
Exclusion Criteria:
- Children older than 48 months at enrolment.
- Primary family carers unable to read or understand Chinese.
- Primary family carers with cognitive impairments that prevent questionnaire completion.
- Absence of written informed consent.
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Acute Illness Group
Children aged 0-48 months diagnosed with acute illnesses, including pneumonia (n=90) and acute diarrhoea (n=90). Participants will be recruited across different disease severity levels. Their primary family carers will complete proxy-reported health-related quality of life assessments at baseline and follow-up, while also reporting their own health and well-being. |
This study involves longitudinal health-related quality of life assessments of children aged 0-48 months and their primary family carers. Carers will complete the EQ-TIPS-3L and EQ-TIPS-5L as proxy respondents for their children. For children aged 25-48 months, the proxy EQ-5D-Y-5L will also be administered. Carers will additionally complete the EQ-5D-5L with sleep and fatigue bolt-on items and the EQ-HWB-9 to assess caregiver spillover effects. Assessments will be conducted at baseline and follow-up using tablet-based questionnaires. No therapeutic interventions will be assigned as part of the study. |
|
Chronic Illness Group
Children aged 0-48 months diagnosed with chronic conditions, including haematological malignancies (n=90) and asthma (n=90). Participants will represent different levels of disease severity. Their primary family carers will complete proxy-reported health-related quality of life assessments at baseline and follow-up, alongside assessments of their own health and caregiver spillover effects |
This study involves longitudinal health-related quality of life assessments of children aged 0-48 months and their primary family carers. Carers will complete the EQ-TIPS-3L and EQ-TIPS-5L as proxy respondents for their children. For children aged 25-48 months, the proxy EQ-5D-Y-5L will also be administered. Carers will additionally complete the EQ-5D-5L with sleep and fatigue bolt-on items and the EQ-HWB-9 to assess caregiver spillover effects. Assessments will be conducted at baseline and follow-up using tablet-based questionnaires. No therapeutic interventions will be assigned as part of the study. |
|
Healthy Control Group
Group/Cohort Description: Age-matched healthy children aged 0-48 months (n=90), with no known medical conditions at the time of assessment, recruited during routine physical examinations. Their primary family carers will complete the same proxy-reported child health and caregiver health-related quality of life assessments as those in the illness groups. |
This study involves longitudinal health-related quality of life assessments of children aged 0-48 months and their primary family carers. Carers will complete the EQ-TIPS-3L and EQ-TIPS-5L as proxy respondents for their children. For children aged 25-48 months, the proxy EQ-5D-Y-5L will also be administered. Carers will additionally complete the EQ-5D-5L with sleep and fatigue bolt-on items and the EQ-HWB-9 to assess caregiver spillover effects. Assessments will be conducted at baseline and follow-up using tablet-based questionnaires. No therapeutic interventions will be assigned as part of the study. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Known-Groups Validity of EQ-TIPS-3L and EQ-TIPS-5L
Time Frame: Baseline
|
Known-groups validity will be evaluated by comparing EQ-TIPS-3L and EQ-TIPS-5L level sum scores (LSS) across predefined clinical severity categories and overall health assessment (OHA) categories. Cohen's d and relative efficiency based on ANOVA F-statistics will be calculated to assess the instruments' discriminatory ability. |
Baseline
|
|
Test-Retest Reliability of EQ-TIPS-3L and EQ-TIPS-5L
Time Frame: Baseline and follow-up (at least 3 days after baseline; timing varies by clinical condition)
|
Test-retest reliability will be evaluated among children whose health status remains stable between baseline and follow-up, as determined by unchanged clinical severity and overall health assessment (OHA). Intraclass correlation coefficients (ICCs) will be calculated for EQ-TIPS level sum scores (LSS), and Gwet's agreement coefficients will be calculated for individual dimensions. |
Baseline and follow-up (at least 3 days after baseline; timing varies by clinical condition)
|
|
Responsiveness of EQ-TIPS-3L and EQ-TIPS-5L to Changes in Child Health
Time Frame: Baseline and follow-up (at least 3 days after baseline; timing varies by clinical condition)
|
Responsiveness will be evaluated by changes in EQ-TIPS-3L and EQ-TIPS-5L scores between baseline and follow-up among children classified as improved, stable, or deteriorated based on clinical indicators and overall health assessment (OHA). Standardised effect size (SES), standardised response mean (SRM), and Paretian Classification of Health Change (PCHC) will be calculated. |
Baseline and follow-up (at least 3 days after baseline; timing varies by clinical condition)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Face Validity and Acceptability of EQ-TIPS-3L and EQ-TIPS-5L
Time Frame: Baseline
|
Face validity and acceptability will be assessed using the QQ-10 questionnaire completed by family carers. Quantitative responses will evaluate perceived value, clarity, relevance, and acceptability. Open-ended responses will undergo thematic content analysis to identify concerns regarding comprehensiveness, redundancy, and questionnaire burden. |
Baseline
|
|
Comparative Psychometric Performance of EQ-TIPS-3L and EQ-TIPS-5L
Time Frame: Baseline and follow-up (at least 3 days after baseline; timing varies by clinical condition)
|
EQ-TIPS-3L and EQ-TIPS-5L will be compared in terms of missing responses, response distributions, ceiling effects, known-groups validity, test-retest reliability, and responsiveness to health change. Ceiling effects will be assessed using the proportion of children reporting no problems across all dimensions. |
Baseline and follow-up (at least 3 days after baseline; timing varies by clinical condition)
|
|
Psychometric Performance of EQ-5D-5L With Sleep and Fatigue Bolt-Ons and EQ-HWB-9 in Family Carers
Time Frame: Baseline and follow-up (at least 3 days after baseline; timing varies by clinical condition)
|
Caregiver outcomes will be evaluated using EQ-5D-5L with sleep and fatigue bolt-on items and EQ-HWB-9. Analyses will assess response distributions, ceiling effects, known-groups validity, test-retest reliability, and responsiveness to changes in child health. Regression analyses will explore associations with child disease severity, caregiving time, and caregiver burden. |
Baseline and follow-up (at least 3 days after baseline; timing varies by clinical condition)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Signs and Symptoms, Digestive
- Immune System Diseases
- Respiratory Tract Infections
- Infections
- Respiratory Tract Diseases
- Lung Diseases
- Bronchial Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity, Immediate
- Hypersensitivity
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Asthma
- Disease
- Pneumonia
- Diarrhea
Other Study ID Numbers
Other Study ID Numbers
- EQ Project 2152-RA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.